Protagonist Therapeutics, Inc. reported $282M of revenue over the trailing twelve months, +35% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $282M (to Q2 2026). Net income: $83M, trailing twelve months to Q2 2026. Free cash flow: $131M, trailing twelve months to Q2 2026. Operating margin: −399%, trailing twelve months to Q2 2026.

PTGXProtagonist Therapeutics, Inc.

Healthcare

$143.75+131% 1Y

$143.75

$64.0052 weeks$158.64

PTGX as reported

Protagonist Therapeutics, Inc. reported $282M of revenue over the trailing twelve months, +35% on the year before. 9 reported series are charted on this page, each one as filed.

$282M

Revenue, trailing twelve months · to Q2 2026 · +35% against the twelve months before

Net income: $83M
Net income · +59% year on year · trailing twelve months to Q2 2026
Free cash flow: $131M
Free cash flow · +252% year on year · trailing twelve months to Q2 2026
Operating margin: −399%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PTGX, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$282M	+35%	Q2 2026
Net income	$83M	+59%	Q2 2026
EPS	$1.02	+40%	Q2 2026
Operating margin	−399%	n/a	Q2 2026
Net margin	−337%	n/a	Q2 2026
ROE	−5.4%	n/a	Q2 2026
ROA	−5.0%	n/a	Q2 2026
Free cash flow	$131M	+252%	Q2 2026
P/E	141	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.